Steroid-free immunosuppression after renal transplantation - Long-term experience from a single centre

Nephrology Dialysis Transplantation

Volumn 21, Issue 7, 2006, Pages 1966-1973

  El Faramawi, Mohamad ^a   Rohr, Nils ^a   Jespersen, Bente ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Long term; Renal transplantation; Steroid free

Indexed keywords

ACICLOVIR; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CEFUROXIME; CYCLOSPORIN A; ENOXAPARIN; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY; VALACICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DENMARK; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; EXPERIENCE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MUROMONAB-CD3; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME;

EID: 33745593706     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl131     Document Type: Article

References (28)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289-1295
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612
3. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147: 645-657
4. Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643-648
5. Montagnino G, Tarantino A, Segoloni GP et al. Long-term results of a randomized study comparing three immunosuppressive schedules with cyclosporine in cadaveric kidney transplantation. J Am Soc Nephrol 2001; 12: 2163-2169
6. Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865-1874
7. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H, for the Steroid Dosing Study Group. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352-1359
8. Vanrenterghem Y, van Hooff JP, Squifflet JP et al. Minimization of immunosuppressive therapy after renal transplantation: Results of a randomized controlled trial. Am J Transplant 2005; 5: 87-95
9. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814
10. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311
11. Khwaja K, Asolati M, Harmon J et al. Outcome at 3 years with a prednisone-free maintenance regimen: A single-center experience with 349 kidney transplant recipients. Am J Transplant 2004; 4: 980-987
12. Vincenti F. Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients. Transpl Int 2004; 17: 395-401
13. Parrott NR, Hammad AQ, Watson CJ, Lodge JP, Andrews CD. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. Transplantation 2005; 79: 344-348
14. Vidhun JR, Sarwal MM. Corticosteroid avoidance in pediatric renal transplantation. Pediatr Nephrol 2005; 20: 418-426
15. Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845-850
16. Birkeland SA. Steroid-free immunosuppression in renal transplantation: A long-term follow-up of 100 consecutive patients. Transplantation 2001; 71: 1089-1090
17. Ejersted C, Jensen JD, Jespersen B et al. Bone density after renal transplantation in relation to immnunosuppressive therapy: A follow-up study. J Bone Miner Res 2004, Abstact M546
18. Birkeland SA, Larsen KE, Rohr N. Pediatric renal transplantation without steroids. Pediatr Nephrol 1998; 12: 87-92
19. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. Bio Drugs 2001; 15: 279-290
20. Their M, von Willebrand E, Taskinen E, Ronnholm K, Holmberg C, Jalanko H. Fine-needle aspiration biopsy allows early detection of acute rejection in children after renal transplantation. Transplantation 2001; 71: 736-743
21. Birkeland SA, Bendtzen K, Moller B, Hamilton-Dutoit S, Andersen HK. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999; 67: 876-881
22. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76: 984-988
23. Lebranchu Y, Bridoux F, Buehler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56
24. Filler G, Webb NJ, Milford DV et al. Four-year data after pediatric renal transplantation: A randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 2005; 9: 498-503
25. Elias TJ, Bannister KM, Clarkson AR et al. Excellent longterm graft survival in low risk, primary renal allografts treated with prednisolone-avoidance immunosuppression. Clin Transplant 2000; 14: 157-161
26. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72 [Suppl 6]: S5-S8
27. Cytomegalovirus. Am J Transplant 2004; 4 [Suppl 10]: 51-58
28. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829-839